Clinical and immunological effects of choline alfoscerate in the treatment of amnestic type Mild Cognitive Impairment

Kolykhalov I.V.; Androsova L.V.; Gavrilova S.I.

doi:https://doi.org/10.17116/jnevro202212211259

Close metadata

OBJECTIVE

To evaluate the change of a number of clinical and immunological parameters of patients with amnestic type Mild Cognitive Impairment (aMCI) in the course of therapy with Choline alfoscerate (α-GPC) in order to develop a monitoring and predicting system of its effectiveness in people at risk for Alzheimer’s disease.

MATERIAL AND METHODS

Thirty patients with aMCI, aged 56 to 82 years (mean age 68.8±9.4 years), received course therapy with α-GPC in capsules of 400 mg 3 times a day (1200 mg per day) for 3 months. Therapeutic efficacy evaluation according to psychometric tests and scales was carried out three times (0, 45 and 90 days), immunological parameters of leukocyte elastase (LE) and α1-protease inhibitor (α1-PI) were evaluated twice on days 0 and 90 of therapy.

RESULTS

A good therapeutic effect over the course treatment with α-GPC, both in terms of cognitive functioning and a number of immunological parameters in patients with aMCI was shown. Significant clinical and immunological correlations included both an improvement in cognitive functions (according to MMSE and the Boston Naming Test) and an increase in LE activity level after the completion of a course of α-GPC therapy, which suggest that an increase in LE functional activity can be considered as a potential marker of a positive therapeutic response to α-GPC treatment in aMCI patients.

CONCLUSION

This study shows high significance of further research in assessing the role of immune mechanisms of α-GPC therapeutic efficacy in aMCI patients and the possibility of using immunological parameters as prognostic markers of its therapeutic effect.

Keywords:

mild cognitive impairment (MCI)

inflammatory markers

leukocyte elastase

acute phase proteins

therapy

choline alfoscerate

Authors:

Kolykhalov I.V.

Mental Health Research Center

ORCID: 0000-0002-2358-1579

Androsova L.V.

Mental Health Research Center

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Received:

13.05.2022

Accepted:

29.05.2022

Close metadata

References:

Castillo X, Castro-Obregón S, Gutiérrez-Becker B, et al. Re-thinking the Etiological Frame work of Neurodegeneration. Front Neurosci. 2019;13:728. https://doi.org/10.3389/fnins.2019.00728
Gan L, Cookson MR, Petrucelli L, LaSpada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018;21:1300-1309. https://doi.org/10.1038/s41593-018-0237-7
Castelli V, Benedetti E, Antonosante A, et al. Neuronal cells rearrangement during aging and neurodegenerative disease: metabolism, oxidative stress and organelles dynamic. Front Mol Neurosci. 2019;12:132. https://doi.org/10.3389/fnmol.2019.00132
Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view. Oxid Med Cell Longev. 2019;2019:1-18. https://doi.org/10.1155/2019/2105607
Hussain R, Zubair H, Pursell S, Shahab M. Neurodegenerative diseases: regenerative mechanisms and novel therapeutic approaches. Brain Sci. 2018;8(9):177. https://doi.org/10.3390/brainsci8090177
Eikelenboom P, Veerhuis R, van Exel E, et al. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer’s disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res. 2011;8(2):142-150. https://doi.org/10.2174/156720511795256080
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388-405. https://doi.org/10.1016/S1474-4422(15)70016-5
Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157-172. https://doi.org/10.1038/s41582-020-00435-y
McFarland KN, Chakrabarty P. Microglia in Alzheimer’s Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis. Neurotherapeutics. 2022 Mar 14. Online ahead of print. https://doi.org/10.1007/s13311-021-01179-3
Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition — the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50:2041-2056. https://doi.org/10.1046/j.1532-5415.2002.50619.x
Liu L, Chan C. The role of inflammasome in Alzheimer’s disease. Ageing Res Rev. 2014;15(1):6-15. https://doi.org/10.1016/j.arr.2013.12.007
Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21(3):383-421. https://doi.org/10.1016/s0197-4580(00)00124-x
Yasojima K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res. 2000;887(1):80-89. https://doi.org/10.1016/s0006-8993(00)02970-x
Varma VR, Varma S, An Y, et al. Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal in jury through the RCAN1 pathway. Mol Psychiatry. 2017;22(1):13-23. https://doi.org/10.1038/mp.2016.206
Simonov AN, Klyushnik TP, Androsova LV, Mikhaĭlova NM. Quantification of the relationship between inflammatory markers and Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(5):58-63. (In Russ.). https://doi.org/10.17116/jnevro20181185158
Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol. 2004;61:668-672. https://doi.org/10.1001/archneur.61.5.668
Schuitemaker A, Dik MG, Veerhuis R, et al. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging. 2008;30(11):1885-1889. https://doi.org/10.1016/j.neurobiolaging.2008.01.014
Veerhuis R, Van Breemen MJ, Hoozemans JM, et al. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol. 2003;105:135-144. https://doi.org/10.1007/s00401-002-0624-7
Dik MG, Jonker C, Hack CE, et al. Serum inflammatory proteins and cognitive decline in older persons. Neurology. 2005;64:1371-1377. https://doi.org/10.1212/01.WNL.0000158281.08946.68
Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168-174. https://doi.org/10.1002/ana.10265
Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76-80. https://doi.org/10.1212/01.wnl.0000073620.42047.d7
Soares HD, Potter WZ, Pickering E, et al. Biomarkers Consortium Alzheimer’s Disease Plasma Proteomics Project. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol. 2012;69(10):1310-1317. https://doi.org/10.1001/archneurol.2012.1070
Doecke JD, Laws SM, Faux NG, et al. Alzheimer’s Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012;69(10):1318-1325. https://doi.org/10.1001/archneurol.2012.1282
Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359-1362. https://doi.org/10.1038/nm1653
Klyushnik TP, Androsova LV, Mikhailova NM, et al. Potential markers of Alzheimer’s disease associated with inflammation. Psychiatry. 2014;1(61):28-34. (In Russ.).
Malashenkova IK, Hailov NA, Krynskiy SA, et al. Levels of proinflammatory cytokines and vascular endothelial growth factor in patients with Alzheimer’s disease and mild cognitive impairment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(3):39-43. (In Russ.). https://doi.org/10.17116/jnevro20161163139-43
Gavrilova SI, Vol’pina OM, Kolykhalov IV, et al. Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(8):27-38. (In Russ.). https://doi.org/10.17116/jnevro20171178127-38
Kliushnik TP, Androsova LV, Mikhaylova NM, et al. Systemic Inflammatory Markers in Age-Associated Cognitive Impairment and Alzheimer’s Disease. Neuroscience and Behavioral Physiology. 2019;49(3):352-356. https://doi.org/10.1007/s11055-019-00739-7
Cuello AC, Pentz R, Hall H. The brain NGF metabolic pathway in health and in Alzheimer’s pathology. Front Neurosci. 2019;13:62. https://doi.org/10.3389/fnins.2019.00062
Bothwell M. NGF, BDNF, NT3, and NT4. Handb Exp Pharmacol. 2014;220:3-15. https://doi.org/10.1007/978-3-642-45106-5_1
Jazvinšćak Jembrek M, Hof PR, Šimić G. Ceramides in Alzheimer’s Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation. Oxid Med Cell Longev. 2015;2015:346783. https://doi.org/10.1155/2015/346783
Castelli V, Grassi D, Bocale R, et al. Diet and brain health: Which role for polyphenols? Current Pharmaceutical Design. 2018;24(2):227-238. https://doi.org/10.2174/1381612824666171213100449
Lee SH, Choi BY, Kim JH, et al. Late treatment with choline alfoscerate (l‐alpha glycerylphosphorylcholine, α‐GPC) increases hippocampal neurogenesis and provides protection against seizure‐induced neuronal death and cognitive impairment. Brain Research. 2017;1654(PtA):66-76. https://doi.org/10.1016/j.brainres.2016.10.011
Gallelli L. Choline alphoscerate pharmacology and its role in the treatment of cognitive impairment related to neurological disorders. Funct Neurol. 2011;(suppl 1):1-7.
Amenta F, Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer’s disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev. 2001;122(16):2025-2040. https://doi.org/10.1016/s0047-6374(01)00310-4
Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer’s disease. Biochem Soc Trans. 2004;32:144-146. https://doi.org/10.1042/bst0320144
Yadav RS, Tiwari NK. Lipid integration in neurodegeneration: an overview of Alzheimer’s disease. Molecular Neurobiology. 2014;50(1):168-176. https://doi.org/10.1007/s12035-014-8661-5
Alesenko AV, Gavrilova SI, Gutner UA, et al. Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(6):21-27. (In Russ.). https://doi.org/10.17116/jnevro20171176121-27
Gavrilova SI, Alesenko AV, Kolykhalov IV, et al. Clinical and biological effects of Cereton in the treatment of mild cognitive decline syndrome of the amnesic type. Psychiatry. 2017;(73):5-15. (In Russ.).
Walter J, van Echten-Deckert G. Cross-talk of membrane-lipids and Alzheimer-related proteins. Molecular Neurodegeneration. 2013;8:34. https://doi.org/10.1186/1750-1326-8-34
Jana M, Palencia CA, Pahan K. Fibrillar amyloid-β peptides activate microglia via TLR2: implications for Alzheimer’sdisease. The Journal of Immunology. 2008;181(10):7254-7262. https://doi.org/10.4049/jimmunol.181.10.7254
Marchesini N, Hannun YA. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochemistry and Cell Biology. 2004;82(1):27-44. https://doi.org/10.1139/o03-091
Panchal M, Gaudin M, Lazar AN, et al. Ceramides and sphingomyelinases in senile plaques. Neurobiology of Disease. 2014;65:193-201. https://doi.org/10.1016/j.nbd.2014.01.010
Barth BM, Gustafson SJ, Kuhn TB. Neutral sphingomyelinase activation precedes NADPH oxidase-dependent damage in neurons exposed to the proinflammatory cytokine tumor necrosis factor-α. Journal of Neuroscience Research. 2012;90(1):229-242. https://doi.org/10.1002/jnr.22748